# **M** OLECULAR CHARACTERIZATION OF METALLO-B-LACTAMASE (MBL)-PRODUCING PSEUDOMONAS AERUGINOSA STRAINS FROM RUSSIA

## O. Shevchenko, V. Kretchikov, M. Edelstein and L. Stratchounski

#### **INTRODUCTION AND PURPOSE**

Carbapenems have potent antibacterial activity and are mainly reserved for the treatment of infections caused by multiresistant nosocomial pathogens, including Pseudomonas aeruginosa. However, isolates of this species can develop resistance to carbapenems through alteration of outer membrane permeability, activation of efflux systems or acquisition of carbapenem-hydrolyzing  $\beta$ -lactamases. Production of acquired metallo- $\beta$ -lactamases (M $\beta$ Ls) is probably the most important mechanism of resistance to carbapenems both in terms of its effectiveness and epidemiological significance. The MβL-producing *P. aeruginosa* strains have been reported worldwide but predominantly in South East Asia and Europe. This study aimed to determine the types of M $\beta$ Ls produced by Russian P. aeruginosa strains and to assess their possible genetic relationship.

#### MATERIALS AND METHODS

**Bacterial strains.** A total of 48 nosocomial isolates of *P. aeruginosa* that were suspected to produce MβLs based on results of EDTAdouble-disk synergy test [1] were included in this study. All the isolates were collected as part of the RESORT national surveillance study in 2002-2004. The putative MBL producers were isolated in 6 hospitals located in 3 geographically distant regions of Russia: Krasnodar (Southern Federal District), Moscow (Central Federal District) and Omsk (Siberian Federal District) (Fig. 1).

**Detection of blavim and blaimp genes.** The genes for VIM- and IMPtype  $M\beta Ls$  were detected by real-time PCRs. The consensus primers used in these PCRs were designed to anneal to the conserved regions of  $bla_{VIM}$  and  $bla_{IMP}$  genes, respectively (Tab. 1). The 25-µl PCR mixtures contained: 0.5µM of each primer, 200µM of each dNTP, 1.5mM MgCl<sub>2</sub>, 67mM Tris-HCl (pH=8.3), 17mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1% Tween-20, 0.12mg/ml BSA, 8% Glycerol, 2.5U of DiaTaq polymerase (AmpliSens, Russia), 1µl of SYBR Green I (1:1000 dilution in DMSO, BioGene, UK) and 3µl of template DNA prepared by rapid boiling of 2-3 bacterial colonies in 1mM TE buffer. Amplification was performed in a Rotor-Gene 2000 Real-Time Cycler (Corbett Research, Australia) under the following conditions: 95°C for 2 min, followed by 35 cycles of 95°C for 15 sec,  $63^{\circ}C$  (for bla<sub>VIM</sub> gene) or  $50^{\circ}C$  (for bla<sub>IMP</sub> gene) for 15 sec,




Figure 1. Geographic locations of the hospitals surveyed in RESORT study. The cities where the M $\beta$ L-producing strains were isolated are marked by red flags.

72°C for 15 sec. The final elongation step was at 72°C for 3 min. Melting of amplification products was performed by increasing the temperature from 72 to 94°C by 1°C every 10 sec. Fluorescence of SYBR Green I was acquired on the "SYBR" channel at the end of each amplification cycle and during the melting analysis.

**DNA sequencing.** PCR products corresponding to the internal fragments of blavim and blaimp genes were directly sequenced on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Stafford, TX). Sequences were identified using the BLAST algorithm available through NCBI. The most closely matching sequences (GenBank Acc. No. AY507153 and AY625689) were then used to design the primers for amplification and sequencing of the entire coding regions of *blavim* and *blaimp* genes (Tab. 1).

Primer	Sequence, 5'-3'	Application
VIM-F	GGTGTTTGGTCGCATATCGC	<b>Real-time-PCR</b> detection
VIM-R	CGATCGTCATGAAAGTGCGT	<b>Real-time-PCR</b> detection
IMP-F	GCTAAAGATACTGAAAAATTAGT	<b>Real-time-PCR</b> detection
IMP-R	TCATTTGTTAATTCAGATGCATA	<b>Real-time-PCR</b> detection
VIM-BIG-F	TCTATTTGACCGCGTCTATCAT	PCR and sequencing
VIM-BIG-R	AACGACTGAGCGATTTGTGTGC	PCR and sequencing
IMP-BIG-F	CTACCGCAGCAGAGTCTTTGCC	PCR and sequencing
IMP-BIG-R	CGTTTAACCCTTTAACCGCCTG	PCR and sequencing
M13	GAGGGTGGCGGTTCT	RAPD typing
OPB-17	AGGGAACGAG	<b>RAPD</b> typing

Table 1. Primers used in this study.

Molecular typing. RAPD typing with primers M13 and OPB-17 (Tab. 1) was used to determine clonality between the M $\beta$ Lproducing strains. Amplifications were performed using the Ready-To-Go RAPD Beads (Amersham Biosciences, Piscataway, NJ) as described previously [2]. Cluster analysis of combined RAPD profiles was performed using the GelCompar software v. 4.1 (Applied Maths BVBA, Sint-Martens-Latem, Belgium) with Pearson correlation coefficient and unweighted pair-group method with arithmetic averages (UPGMA) algorithm.

**Resistance transfer by conjugation.** Broth mating of the representative VIM- and IMP-MβL-producing *P. aeruginosa* isolates (one isolate per hospital, per genotype) with *E. coli* AB1456 (F- Rifr) strain was utilized to analyze transferability of carbapenem-resistance determinants. Mating mixtures (initial donor/recipient ratio = 0.01) were incubated at 30°C for 12 h. Selection of transconjugants was attempted on MH agar containing rifampin (150  $\mu$ g/ml) and ceftazidime (4  $\mu$ g/ml) or rifampin and meropenem (0.25  $\mu$ g/ml).

#### RESULTS

**Positive results of PCR with** *bla*<sub>VIM</sub> **gene-specific primers were** obtained for 45 strains expressing the M $\beta$ L phenotype. The remaining three isolates from a single Moscow hospital gave positive results of amplification with *bla*<sub>IMP</sub>-targeting primers (Tab. 2).

Sequencing of the entire *blavim* genes from five representative isolates (one per hospital): 565, 1913, 3389, 2074, 257, revealed their identity to *bla*<sub>VIM-2</sub> (GenBank Acc. No. AY507153).

Sequences of the *bla*<sub>IMP</sub> genes from isolates 3107, 3110, and 3116

Table 2. Chara	cteristics	of	<b>M</b> β <b>L</b> -positive/	
P. aeruginosa s				

Location/	No. of	MBL	RAPD
Hospital	MBL+ strains	type	type
Omsk	37	VIM-2	Α
Moscow 1	5	VIM-2	Α
Moscow 2	1	VIM-2	Α
Moscow 3	1	VIM-2	D
Krasnodar	1	VIM-2	В
Moscow 4	3	IMP-1 (E59K)	С

were all identical and differed from *bla*<sub>IMP-1</sub> (GenBank Acc. No. AY625689) by a single G/A transition at position 121 of the structural gene, corresponding to E59K amino acid change (BBL numbering). Sequence of the gene for identified IMP-1 newly **β-lactamase variant was** deposited in GenBank under accession number DQ061191.

### Inst. of Antimicrobial Chemotherapy, Smolensk, Russia

**Cluster analysis of RAPD** profiles (Fig. 2) suggested that the majority of VIM-2 producers, including all isolates from Omsk and 6 isolates from two Moscow hospitals, belonged to a single clonal group  $(\geq 81.5\%$  identity of profiles). **One VIM-2-producing strain** from Krasnodar and, surprisingly, three IMPproducing isolates had the **RAPD** profiles, designated **B** and C, similar to those of the major group A (69% of the overall identity). The remaining VIM-2-producing strain from Moscow hospital 3 was apparently unrelated (profile D).

**Despite multiple attempts,** broth mating of five VIM-(565, 1913, 3389, 2074, 257) and one IMP-positive (3107) isolates with E. coli AB1456 recipient produced no transconjugants.




Figure 2. UPGMA clustering of combined RAPD profiles of M<sup>β</sup>L-producing *P. aeruginosa* isolates.

#### CONCLUSION

This study for the first time reports the wide geographic dissemination of VIM-2-producing P. aeruginosa strains in Russia as well as the identification of a novel IMP-1 $\beta$ -lactamase variant.

The results of molecular typing suggest a possible genetic relatedness of the majority of M<sub>β</sub>L-producing isolates.

#### REFERENCES

1. Stratchounski L., et al., 408/81P at 6th ECC, Paris, 2004 (IJAA, 2004; 24S:S145). 2. Edelstein M., et al, Antimicrob Agents Chemother. 2004; 48(8):2808-15.

P.O. Box 5, Smolensk, 214019, Russia, email: me@antibiotic.ru, http://www.antibiotic.ru